User:Reetii/sandbox
History:
Lamivudine/Zidovudine (Brand name Combivir) was introduced to the market with FDA licensure in 1997. It's impact in history is significant as it was the first combination therapy with a fixed dose for HIV positive people, and soon solidified its title as a gold standard as it was the most prescribed NRTI in initial HIV treatment for newly diagnosed patients. The arrival of Combivir was seen as a new revolution in HIV therapy, with its improved toxicity profile and tolerability, especially compared to the undesirable side effects of lone AZT therapy or the unfavorable facial and lipoatrophy seen in Stavudine monotherapy at that time. [1]
Drug Formulations: Oral tablets
- Combivir: Lamivudine 150mg and Zidovudine 300mg (scored). 60 Tablets cost $1081.70
- Generic: Lamivudine 150mg and Zidovudine 300mg. 60 Tablets cost $931.61[2]
Society/Culture:
Lamivudine/Zidovudine (Brand name Combivir) is on the World Health Organization's List of Essential Medicines, the 2015 list of necessary medications. [3][4]
 | This is a user sandbox of Reetii. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
- ^ "The renaissance of fixed dose combinations: Combivir". Therapeutics and Clinical Risk Management 2007. 3(4) 579-583.
- ^ "Lexicomp: Lamivudine and Zidovudine".
- ^ "WHO Model List of Essential Medicines". Wikipedia. 2016-10-31.
- ^ "WHO Model Lists of Essential Medicines". World Health Organization. Retrieved 2016-11-07.